An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

Clinical trial NCT07680257 · RECRUITING

Trial details

NCT number: NCT07680257
Sponsor: Celest Therapeutics (Shanghai) Co., Ltd.
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

CLDN18.2 Positive Solid Tumors

Start date: 2025-12-27
Primary completion: 2027-12-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.